SCHEMBL5545407

SCHEMBL5545407

Cc1nc(-c2ccccc2F)oc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
GAA P10253 1/20 0.50
KDM4E B2RXH2 3/20 0.49
C1R P00736 1/20 0.49
F2 P00734 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NOTUM Q6P988 2/20 0.45
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.45
F10 P00742 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545403 0.82 NPC1 (0.47) NPC1RAB9ASMN1; SMN2GAAKDM4E
SCHEMBL5546618 0.82 NPC1 (0.47) NPC1RAB9ASMN1; SMN2GAAKDM4E
SCHEMBL4363143 0.78 POLB (0.51) SMN1; SMN2GAAALDH1A1MEN1KMT2A
SCHEMBL5539532 0.78 TP53 (0.55) NPC1RAB9ASMN1; SMN2KDM4EC1R
SCHEMBL11624472 0.76 NPC1 (0.50) NPC1RAB9ASMN1; SMN2GAAKDM4E
Hydrochloric Acid SCHEMBL11626901 0.76 NPC1 (0.49) NPC1RAB9ASMN1; SMN2GAAC1R
SCHEMBL11621840 0.76 IKBKB (0.56) NPC1RAB9ASMN1; SMN2GAAMEN1
SCHEMBL11626894 0.76 POLB (0.46) SMN1; SMN2C1RF2ALDH1A1MEN1
SCHEMBL5015708 0.76 POLB (0.52) SMN1; SMN2GAAALDH1A1MEN1KMT2A
SCHEMBL11620376 0.74 MAPT (0.47) SMN1; SMN2GAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NPC1 2404/4885RAB9A 2824/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.